- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Breast Cancer Susceptibility Increases With Age and Weight: JAMA Study
A Women's Health Initiative clinical trial has found that overweight or obese postmenopausal women are at an increased risk of aggressive breast cancer.
Published in JAMA Oncology, a randomized clinical trial by the Women's Health Initiative followed 67,142 postmenopausal women with annual or biennial mammography across 40 sites around the country. The women, between 50 and 79 years of age, were followed for a median of 13 years.
The study found that compared with women of normal weight, those who were classified as overweight or obese had a greater risk of developing invasive breast cancer than those who were overweight or obese. Some of the findings of the study include:
- BMI of ≥35, high risk of estrogen receptor—positive breast cancer
- Obesity grade 2 and 3 associated with advanced breast cancer, including large tumor size, positive lymph nodes, and death
- Women who gained >5% body weight during follow-up were at an increased risk of breast cancer
The authors conclude that this study should motivate obesity prevention programs.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
